TGTX — TG THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1001316 ·
Last close
$39.73
Market Cap
$6.08B
52W High
$44.65
52W Low
$26.76
ADV30
2,103,387
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 204,918,000 | 171,408,000 | 34,795,000 | 19,777,000 | 1,528,837,000 | 442,209,000 | 945,706,000 |
| Dec 2025 | 192,574,000 | 154,432,000 | 50,494,000 | 23,037,000 | 1,063,253,000 | 79,148,000 | 415,233,000 |
| Sep 2025 | 161,709,000 | 133,616,000 | 29,365,000 | 390,895,000 | 1,025,024,000 | 74,081,000 | 417,806,000 |
| Jun 2025 | 141,148,000 | 122,210,000 | 34,843,000 | 28,187,000 | 702,613,000 | 129,126,000 | 426,181,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,772,000
Investing CF
$13,799,000
Financing CF
$-89,729,000
CapEx
$-214,000
Dividends Paid
—
Buybacks
$-91,240,000
EPS Diluted TTM
$2.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,082,015,000
Inventory
$125,586,000
Receivables
$305,628,000
ST Investments
$62,822,000
EBIT TTM
$134,117,000
Pretax Income TTM
$107,390,000
Interest Exp TTM
$26,727,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$700,348,992
EBITDA
$149,580,000
Free Cash Flow
$-30,164,876
Enterprise Value
$5,747,900,416
Total Cash
$514,430,016
Total Debt
$753,556,992
Shares Out
153,083,580
Trailing EPS
$2.86
Book Value
$4.52
ROE
112.6%
ROA
8.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 616,287,000 | 123,324,000 | 447,179,000 | 1,063,253,000 | 415,233,000 | — | -24,772,000 |
| Dec 2024 | 329,004,000 | 41,929,000 | 23,383,000 | 577,690,000 | 355,326,000 | — | -40,517,000 |
| Dec 2023 | 233,662,000 | 20,633,000 | 12,672,000 | 329,587,000 | 169,085,000 | — | -31,413,000 |
| Dec 2022 | 2,785,000 | -218,316,000 | -223,812,000 | 193,572,000 | 134,985,000 | — | -176,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.73
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TERN | Terns Pharmaceuticals, Inc. | $6.12B | $52.95 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.03B | $98.90 | — |
| CNTA | Centessa Pharmaceuticals plc | $6.16B | $39.78 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.16B | $89.82 | — |
| ALKS | Alkermes plc. | $6.23B | $37.35 | — |
News headlines (Yahoo Finance, 1h cache)
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
2026-05-26 11:30 · Yahoo
Multiple Sclerosis-Focused Biotech Quadruples Its Profit, Raises Sales Forecast
2026-05-21 16:24 · Yahoo
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
2026-05-20 14:51 · Yahoo
TG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They Appear
2026-05-13 11:44 · Yahoo
Signal Says Which Biotech to Buy This Week
2026-05-11 18:00 · Yahoo
Why TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI Strength
2026-05-10 14:09 · Yahoo
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
2026-05-10 11:59 · Yahoo
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
2026-05-10 09:53 · Yahoo
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum
2026-05-10 00:22 · Yahoo
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
2026-05-08 19:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.